Together, everyone at Synageva shares a passion and commitment to improving the lives of patients suffering from rare diseases.

We believe that Every Second Counts when discovering, developing, and delivering therapies to these patients.

Learn More


Synageva BioPharma Corp. is a biopharmaceutical company with headquarters, research and development facilities in Lexington, MA. Our mission is to deliver breakthrough medicines globally for patients suffering from rare, devastating diseases. Our team has a proven track record of delivering life-altering therapies to patients with diseases once considered too rare for developing treatments.

Learn More

News & Events

April 23, 2014
Click here to read President & CEO, Sanj K. Patel's Letter to Shareholders and 2013 Annual Report.

April 21, 2014
LAL Deficiency Disease Review Published In Atherosclerosis

March 5, 2014
Synageva BioPharma Announces Pricing Of Public Offering Of Common Stock

March 4, 2014
Synageva BioPharma Announces a 2.00 Million Share Proposed Public Offering Of Its Common Stock

March 4, 2014
Synageva BioPharma Issued U.S. Patent for Treatment of LAL Deficiency

March 3, 2014
Synageva BioPharma Reports 2013 Full Year Financial Results

February 28, 2014
Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2014

February 21, 2014
Synageva Biopharma™ To Present At The Cowen And Company Health Care Conference

February 18, 2014
Synageva BioPharma To Host 2013 Fourth Quarter And Full Year Financial Results Conference Call On March 3rd

February 13, 2014
Synageva Biopharma Highlights Sebelipase Alfa And LAL Deficiency Data At The Lysosomal Disease Network (LDN) World Symposium

February 12, 2014
Synageva Biopharma Highlights SBC-103 Data At The Lysosomal Disease Network (LDN) World Symposium

January 29, 2014
Synageva Biopharma Announces Data Presentations At The 10th Annual Lysosomal Disease Network (LDN) World Symposium

January 14, 2014
Click Here To Listen To Synageva's Presentation At The 32nd Annual J.P. Morgan Healthcare Conference

January 6, 2014
Synageva BioPharma Provides Clinical Trial Updates With Sebelipase alfa In LAL Deficiency

December 2, 2013
Synageva BioPharma Completes Target Enrollment In Phase 3 ARISE Trial With Sebelipase alfa In Children And Adults with LAL Deficiency

October 11, 2013
Synageva BioPharma Highlights Data At The NASPGHAN Meeting

September 4, 2013
Synageva BioPharma Highlights Data At The International Congress Of Inborn Errors Of Metabolism

May 31, 2013
Synageva BioPharma Announces Presentations And A Satellite Symposium At The National Lipid Association Meeting

May 20, 2013
Synageva's Sebelipase alfa Receives Breakthrough Therapy Designation For Early Onset LAL Deficiency From The U.S. Food And Drug Administration  

May 9, 2013
Synageva BioPharma Announces One Year Of Treatment Data With Sebelipase alfa In Late Onset LAL Deficiency

March 29, 2013
Early Onset LAL Deficiency (Wolman disease) As Seen In The Washington Post

March 26, 2013
Late Onset LAL Deficiency (CESD) Literature Review Published In The Journal Of Hepatology

February 11, 2013
Synageva BioPharma Initiates Dosing In Phase 3 Trial Of Sebelipase alfa In Children And Adults With Late Onset LAL Deficiency
February 4, 2013
Hepatology Publishes 12-Week Phase I/II Extension Study Data Of Sebelipase alfa In Adults With Late Onset LAL Deficiency

November 19, 2012

Click here to watch The Balancing Act, Lifetime network's segment on LAL Deficiency

November 3, 2011
Click here to watch President and CEO, Sanj K. Patel's NASDAQ Global Market opening presentation

    More News